Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905512 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
A Phase 2 study of Chronic Gout, sponsored by Selecta Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT03905512: Completed Phase 2 study of Chronic Gout, sponsored by Selecta Biosciences.
NCT03905512 is a Phase 2 study of Chronic Gout that has completed, run by Selecta Biosciences. The registered enrollment target is 170 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03905512, a Phase 2 study of Chronic Gout, has completed, sponsored by Selecta Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, parallel-arm, multicenter study to compare the safety and efficacy profiles of SEL-212 and KRYSTEXXA®. Participants will be randomized 1:1 to receive treatment with SEL-212 or KRYSTEXXA® for 6 months. Efficacy assessments, as measured by serum uric acid (SUA) levels, will be conducted at intervals that are appropriate to determine treatment effect differences. Safety will be monitored throughout the study.
Primary Outcome
The average of the data collected during Month 3 and Month 6 was reported.
Conditions Studied
Interventions
- DRUG SEL-212
- DRUG KRYSTEXXA®
Study Locations (20)
Florida
- Clinical Research of West Florida - Clearwater
- QPS-Medical Research Assoc LLC - Miami
- Well Pharma Medical Research Corp. - Miami
- Panax Clinical Research - Miami Lakes
- Accelerated Enrollment Solutions (AES) - Orlando
- Rheumatology Associates of Central Florida, PA - Orlando
- Clinical Research of West Florida, Inc. - Tampa
- Advent Health Group Multispecialty at Habana and Bruce B. Downs - Tampa
California
- Medvin Clinical Research - Covina
- Valerius Medical Group and Research Center of Greater Long Beach, Inc. - Los Alamitos
- Arthritis Care and Research Center - Poway
- MD Strategies Research Centers - San Diego
Georgia
- Arthritis Center of North Georgia - Gainesville
- Better Health Clinical Research, Inc. - Newnan
Alabama
- Pinnacle Research Group, LLC - Anniston
Arizona
- Arizona Arthritis & Rheumatology Research, PLLC - Sun City
Arkansas
- Baptist Health Center for Clinical Research - Little Rock
Idaho
- Institute of Arthritis Research - Idaho Falls
Illinois
- Great Lakes Clinical Trials - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2019-05-07 |
| Est. Completion | 2020-08-05 |
| Phase | Phase 2 |
What the finished NCT03905512 record still lists
NCT03905512 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Chronic Gout appearing as the primary indexed condition, and to 2 interventions - of which SEL-212 is the first listed.
NCT03905512 names 20 study sites across 9 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03905512 about?
NCT03905512 is a clinical study titled "A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy". This is a randomized, parallel-arm, multicenter study to compare the safety and efficacy profiles of SEL-212 and KRYSTEXXA®. Participants will be randomized 1:1 to receive treatment with SEL-212 or KRYSTEXXA® for 6 months. Efficacy assessments, as measured by serum uric acid (SUA) levels, will be co...
What is the current status of trial NCT03905512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2019-05-07. Estimated completion is 2020-08-05.
What conditions does trial NCT03905512 study?
This clinical trial studies the following conditions: Chronic Gout.
What interventions are being tested in trial NCT03905512?
The interventions under investigation include: SEL-212 (DRUG), KRYSTEXXA® (DRUG).
Who is sponsoring clinical trial NCT03905512?
This trial is sponsored by Selecta Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03905512 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03905512's enrollment target sits among peer trials
170 399th of 2000 higher than 1,598 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI